Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for connective tissue disease-associated interstitial lung disease
NL-OMON61156Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of belimumab in connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by GSK. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
belimumab
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NL-OMON61156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61156.